bexmarilimab   Click here for help

GtoPdb Ligand ID: 12907

Synonyms: Clevegen | FP-1305 | FP1305
Immunopharmacology Ligand
Compound class: Antibody
Comment: Bexmarilimab (FP-1305; Faron Pharmaceuticals) is a humanized anti-CLEVER-1 (stabilin 1; STAB1) IgG4-antibody [1]. It switches immunosuppressive M2 macrophages to immune-stimulating M1 macrophages, activates T cells and restores T cell-dependent killing of cancer cells. Bexmarilimab is a cancer immunotherapy clinical candidate [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Bexmarilimab (FP-1305) has been entered into clinical trials to evaluate its safety and efficacy as a treatment for advanced solid tumours and hematological malignancies. The FDA granted bexmarilimab orphan designation in August 2023, to treat acute myeloid leukemia (AML).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05428969 A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB) Phase 1/Phase 2 Interventional Faron Pharmaceuticals Ltd
NCT05171062 Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer Phase 1 Interventional The University of Texas Health Science Center at San Antonio
NCT03733990 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Phase 1/Phase 2 Interventional Faron Pharmaceuticals Ltd 2